Suppr超能文献

糖皮质激素可抑制性醛固酮增多症的长期演变

Long term evolution of glucocorticoid-suppressible hyperaldosteronism.

作者信息

Stockigt J R, Scoggins B A

出版信息

J Clin Endocrinol Metab. 1987 Jan;64(1):22-6. doi: 10.1210/jcem-64-1-22.

Abstract

It is generally held that idiopathic hyperaldosteronism and glucocorticoid-suppressible hyperaldosteronism (GSH) are distinct entities, distinguishable by thorough investigation. We report a patient who presented in 1974 at age 15 yr with blood pressure of 240/120 mm Hg, serum K of 3.1 mM, low renin, and high normal aldosterone excretion, with findings diagnostic of GSH. After dexamethasone treatment (2 mg/day for 4 weeks), urinary aldosterone was undetectable (less than 1 microgram/24 h), associated with correction of hypertension and hypokalaemia. While untreated, plasma aldosterone increased in response to ACTH infusion at a dose that did not influence plasma cortisol. Plasma aldosterone at 0800 h while recumbent was higher than in subsequent samples taken while ambulant, consistent with ACTH dependence of aldosterone secretion. Blood pressure, renin, and potassium remained normal for 4 yr during treatment with dexamethasone (0.5-0.75 mg/day), but hypertension then slowly returned. After 7 yr, the original studies were repeated. Urinary aldosterone excretion was again in the high normal range after 3 weeks of no treatment, but both plasma renin and aldosterone consistently increased in response to upright posture. After dexamethasone treatment (2 mg/day) for 4 weeks, urinary aldosterone was not suppressed (excretion rate, 10.8, 9.2, and 5.7 micrograms/day; urinary Na, greater than 100 mmol/day; urinary cortisol, less than 1 microgram/day). At this time, dexamethasone did not alleviate hypertension or increase renin. Control of blood pressure has been readily achieved, 8-12 yr after diagnosis, with a low dose of beta-adrenergic antagonist and amiloride. Aldosterone remains incompletely suppressible during sodium loading, so that the findings now resemble those of idiopathic hyperaldosteronism. This sequence indicates that glucocorticoids may not permanently control hypertension in GSH. The transient dominance of ACTH in control of aldosterone secretion indicates that the relationship between GSH and idiopathic hyperaldosteronism merits further evaluation in long term studies.

摘要

一般认为,特发性醛固酮增多症和糖皮质激素可抑制性醛固酮增多症(GSH)是不同的病症,通过全面检查可加以区分。我们报告了一名患者,该患者于1974年15岁时就诊,血压为240/120 mmHg,血清钾为3.1 mM,肾素水平低,醛固酮排泄处于高正常范围,检查结果诊断为GSH。地塞米松治疗(2 mg/天,共4周)后,尿醛固酮检测不到(低于1微克/24小时),同时高血压和低钾血症得到纠正。未经治疗时,血浆醛固酮在不影响血浆皮质醇的促肾上腺皮质激素(ACTH)输注剂量下会升高。卧位时0800 h的血浆醛固酮高于随后活动时采集的样本,这与醛固酮分泌对ACTH的依赖性一致。在使用地塞米松(0.5 - 0.75 mg/天)治疗期间,血压、肾素和血钾在4年里保持正常,但随后高血压又缓慢复发。7年后,重复进行了最初的检查。在未治疗3周后,尿醛固酮排泄再次处于高正常范围,但血浆肾素和醛固酮在直立姿势下均持续升高。地塞米松治疗(2 mg/天)4周后,尿醛固酮未被抑制(排泄率分别为10.8、9.2和5.7微克/天;尿钠大于100 mmol/天;尿皮质醇低于1微克/天)。此时,地塞米松未能缓解高血压或升高肾素。在诊断8 - 12年后,使用低剂量的β - 肾上腺素能拮抗剂和氨氯吡咪已很容易实现血压控制。在钠负荷期间,醛固酮仍不能被完全抑制,因此现在的检查结果类似于特发性醛固酮增多症。这一系列情况表明,糖皮质激素可能无法永久性地控制GSH患者的高血压。ACTH在醛固酮分泌控制中的短暂主导地位表明,GSH与特发性醛固酮增多症之间的关系值得在长期研究中进一步评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验